Abstract
Multidrug resistance (MDR) remains one of the most formidable obstacles in modern oncological pharmacotherapy, frequently mediated by the overexpression of ATP-binding cassette (ABC) transmembrane efflux transporters such as P-glycoprotein. To circumvent active efflux mechanisms and mitigate off-target systemic toxicity, structural DNA nanotechnology offers unprecedented architectural control for nanoscale biomedical robotics. In this study, we report the design, self-assembly, and functional validation of an autonomous, aptamer-gated DNA origami nanorobot engineered for the precise intracellular delivery of doxorubicin into chemoresistant breast adenocarcinoma cells (MCF-7/ADR). The tubular nanorobot is fabricated using scaffolded DNA origami and held in a closed configuration via duplexed lock strands incorporating the nucleolin-specific AS1411 aptamer. Upon encountering cell-surface nucleolin, conformational reconfiguration triggers autonomous opening, exposing intercalated doxorubicin specifically within the target microenvironment. Transmission electron microscopy and atomic force microscopy confirmed the high-fidelity assembly and ligand-responsive mechanical actuation of the nanorobots. In vitro assays demonstrated robust cellular internalization via endocytosis, bypassing membrane-bound efflux pumps and facilitating lysosomal escape. The nanorobots exhibited a 7.4-fold decrease in the half-maximal inhibitory concentration (IC50) compared to free doxorubicin in MCF-7/ADR cells, while maintaining negligible cytotoxicity toward non-malignant control lines. These findings illustrate the efficacy of smart, reconfigurable DNA nanorobots as versatile therapeutic vectors capable of reversing cancer chemoresistance through targeted supramolecular delivery.